Similar Papers

Paper Title
Journal
Date
Author
Reduced-Intensity Chemotherapy with Mini-Hyper-CVD Plus Inotuzumab Ozogamicin, with or without Blinatumomab, in Older Adults with Newly Diagnosed Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia: Results from a Phase II Study
Nicholas J Short ...
Blood | VOL. 136
Nicholas J Short, et. al.Nicholas J Short ...
05 Nov 2020
Sequential Combination of Inotuzumab Ozogamicin (InO) with Low-Intensity Chemotherapy (Mini-hyper-CVD) with or without Blinatumomab Is Highly Effective in Patients (pts) with Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia (ALL) in First Relapse
Koji Sasaki ...
Blood | VOL. 134
Koji Sasaki, et. al.Koji Sasaki ...
13 Nov 2019
Updated Results from a Phase II Study of Mini-Hyper-CVD Plus Inotuzumab Ozogamicin, with or without Blinatumomab, in Older Adults with Newly Diagnosed Philadelphia Chromosome-Negative B-Cell Acute Lymphoblastic Leukemia
Nicholas J Short ...
Blood | VOL. 138
Nicholas J Short, et. al.Nicholas J Short ...
05 Nov 2021
The Impact of Smoking on Survival in Patients (Pts) with Newly Diagnosed Philadelphia Chromosome Positive (Ph+) Acute Lymphoblastic Leukemia (ALL) Treated with the Combination of Intensive Therapy with Tyrosine Kinase Inhibitor (TKI)
Koji Sasaki ...
Blood | VOL. 134
Koji Sasaki, et. al.Koji Sasaki ...
13 Nov 2019
View more papers

More From: Blood

Paper Title
Journal
Date
Author
Acute myeloid leukemia with BCL6 and KMT2A dual rearrangements
Qiudan Shen ... Shimin Hu
Blood | VOL. 145
Qiudan Shen, et. al.Qiudan Shen ... Shimin Hu
06 Feb 2025
The dark zone of CNS relapse in DLBCL
Kieron Dunleavy
Blood | VOL. 145
Kieron DunleavyKieron Dunleavy
06 Feb 2025
Impact of new medications on the treatment of Immune TTP.
Marie Scully ... William A Lester
Blood | VOL. -
Marie Scully, et. al.Marie Scully ... William A Lester
06 Feb 2025
No exit: targeting RNA export in T-cell malignancy
Katherine L B Borden
Blood | VOL. 145
Katherine L B BordenKatherine L B Borden
06 Feb 2025
View more papers

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.